The demand for GLP-1 medications has exploded. With Google searches for “semaglutide” up 1,400% in three years and headlines touting weight loss miracles, it’s no surprise plan members are scrambling for answers.
But while the public conversation focuses on hype and access, plan sponsors are left facing a different kind of challenge: soaring pharmacy costs, misinformation-driven demand, and a prescribing environment with little built-in cost control.
A recent announcement from Scripta Insights highlights the scale of this confusion. Their approach is to target consumers directly. But tools aimed at patients – after the prescribing decision is made – come too late to control spend.
The Cost of Confusion
GLP-1 drugs are just the latest example of a larger trend: high-cost therapies fueled by direct-to-consumer advertising, celebrity endorsements, and social media hype. Providers are fielding questions about drugs members saw on TikTok, while benefit teams are managing a category that’s grown exponentially, with little visibility or control.
And when coverage criteria or costs get in the way, members often walk away from the pharmacy counter empty-handed. Prior authorization requests spike. Clinics spend hours on phone calls. And plan sponsors pay the price in both dollars and dissatisfaction.
At RazorMetrics, we offer a smarter, easier path: one that supports the physician, respects the member, and reduces unnecessary spend without disrupting clinical care.
Physician-Directed Intervention
Our solution engages prescribers directly and within their normal clinic workflow. That’s where cost, safety, and formulary alignment can truly influence decision-making.
We surface safe, lower-cost therapeutic alternatives, including for GLP-1s, so physicians can make informed choices and reduce unnecessary spend. If the prescriber agrees, the member is then contacted. If not, no further action is taken. That keeps the doctor-patient trust intact and disruptions minimal.
Off-Label Demand, On-Label Costs
GLP-1s are clinically appropriate for some members, particularly those with type 2 diabetes or obesity-related health risks. But not every prescription is driven by medical need. Some reflect off-label use or member requests shaped by marketing, not medicine.
That’s where RazorMetrics can help.
By offering plan-aligned, clinically sound alternatives, including biosimilars and non-GLP therapies, RazorMetrics gives prescribers better options that reduces unnecessary spend and protects access for the patients who truly need these medications.
Prior Auth Fatigue Is Real
In high-cost categories like GLP-1s, denials and prior auth delays are common and costly. Every unnecessary prescription triggers a domino effect: more paperwork, more member frustration, more clinic burnout.
RazorMetrics helps prevent that first domino from falling. When a plan sponsor changes their formulary, RazorMetrics directs physicians toward covered, lower-cost drugs before the prior auth is even submitted. We reduce the burden on staff and improve member experience without ever adding to the physician’s workflow.
GLP-1s Are a Wake-Up Call
This is bigger than one drug class. GLP-1s are just the beginning of a broader trend: high-cost, high-demand therapies that members hear about long before plans can respond. Without clinical guidance and real-time alignment with plan design, cost overruns are inevitable.
RazorMetrics helps plan sponsors get ahead of the curve with a solution that’s proven to lower pharmacy costs. Our model respects physicians, protects members, and helps plan sponsors take control of rising pharmacy costs, starting with GLP-1s, but not ending there. Because at the end of the day, it’s not just about controlling one drug. It’s about instituting a smarter drug cost containment strategy that works across all drug classes at scale.of a broader trend: high-cost, high-demand therapies that members hear about long before plans can respond. Without clinical guidance and real-time alignment with plan design, cost overruns are inevitable.
RazorMetrics helps plan sponsors get ahead of the curve with a solution that’s proven to lower pharmacy costs. Our model respects physicians, protects members, and helps plan sponsors take control of rising pharmacy costs, starting with GLP-1s, but not ending there. Because at the end of the day, it’s not just about controlling one drug. It’s about instituting a smarter drug cost containment strategy that works across all drug classes at scale.
